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Quality of life (QOL) is an important outcome after treatment for upper gastrointestinal tract cancer but few studies report good
accrual and subsequent attrition is usually high. This study investigated the feasibility of a nurse-led service to obtain longitudinal QOL
assessments and explored how clinical and sociodemographic factors influence patients’ need for help to complete questionnaires.
Fully informed patients were invited into the study. Baseline hospital assessments were scheduled by telephone and thereafter by
post unless patients’ health indicated the need for a home visit. In all, 128 out of 140 (91%) baseline QOL assessments were
performed. Follow-up questionnaire completion was good, with 114 patients (89%) completing all but one of the expected
assessments. At baseline, 41 (32%) patients required a lot of help to complete questionnaires. Patients requiring help were more
likely to be undergoing palliative treatment than treatment aimed at cure (68 vs 33%; odds ratio 3.48, Po0.01). Patients’ with
advanced stage cancer of the upper gastrointestinal tract receiving palliative treatment require dedicated staff to ensure good
compliance with longitudinal QOL data collection. It is essential to budget for this in clinical trails.
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The American Society of Clinical Oncology recommends that
assessment of patient outcomes (e.g., survival and quality of life) is
more important than other outcomes (e.g., tumour response rates
and biomarkers) in the evaluation of new technologies and in
development of cancer treatment guidelines (The American
Society of Clinical Oncology, 1996). Survival data are routinely
collected in most clinical trials and many are now including quality
of life (QOL) as a secondary end point. Interest in assessing QOL is
also increasing in routine clinical practice (Detmar and Aaronson,
1998). Quality of life data are valuable end points because they
monitor change in patient-reported symptom experience and
functional health over time and there is evidence to show that they
facilitate communication between doctors and patients (Detmar
et al, 2000). For patients with cancer of the upper gastrointestinal
tract (oesophagus and stomach), these considerations are espe-
cially important, because the disease and treatment (surgery,
endoscopic palliation or chemoradiation therapy) may have
significant morbidity and impact on QOL. Studies attempting to
measure changes in QOL over time in patients with upper
gastrointestinal cancer, have however, frequently reported poor
accrual and high attrition rates with QOL assessments (Barr and
Krasner, 1991; Webb et al, 1997; Ilson et al, 1999; Ross et al, 2002).
These reports often lack details of QOL methods used to collect
data (interview administered or self-completion, reasons for
nonparticipation and attrition). Poor compliance and reporting
of QOL data in clinical trials may bias the results and invalidate
conclusions (Nordin et al, 2001).
Efforts to improve compliance with QOL assessment have
mostly focused on developing psychometrically robust tools and
less about the practical details of administering questionnaires.
Computer-based assessments in outpatient clinics may be used
(Velikova et al, 2002), but this still requires patients to attend the
hospital. In view of the importance of accurate QOL data to help
define treatment for upper gastrointestinal tract cancer, this study
was undertaken with the following aims: to describe a method of
obtaining good compliance with longitudinal QOL measurements
from patients with oesophageal and gastric cancer and to examine
factors that determine whether patients need help to complete
questionnaires.
METHODS
Between November 2000 and November 2001 consecutive new
patients presenting to one upper gastrointestinal unit, with
oesophageal or gastric cancer were considered eligible to
participate in a longitudinal study evaluating the impact of
treatment for oesophageal and gastric cancer on QOL. Patients
were excluded if they were unable to understand the language of
the questionnaire, if they had brain metastases, delirium or
confusion or if they had other previous or concurrent malig-
nancies. There were no limits on age or performance status.
Patients were identified at the upper gastrointestinal cancer
multidisciplinary meeting where all new patients are discussed.
All new patients were informed of the diagnosis and an assessment
of general health was performed before undergoing staging
investigations. Staging investigations included chest and abdom-
inal computerised tomography, selective endoluminal ultrasono-
graphy and where indicated laparoscopy. Patients were then
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rediscussed at the multidisciplinary meeting and a treatment plan
was recommended. The plan was discussed with the patient in
clinic. Informed patients, therefore, aware of the diagnosis and
proposed treatment were invited to take part in this QOL study.
Patients were informed that the purpose of the study was to assess
how the disease and treatment impacts on specific aspects of their
health. They were aware that they would be asked to fill in repeated
questionnaire assessments. Clinical and sociodemographic data
were recorded. Ethics committee permission and written informed
consent were obtained.
Quality of life assessments
Two part time research nurses coordinated data collection.
Baseline interviews were arranged by telephone. Patients attending
the hospital within the time frame for the first assessment
underwent baseline assessment in hospital. Occasionally, patients
who were able were asked to complete postal baseline assessments.
Patients who could not be interviewed in hospital before the start
of treatment and those who did not understand the nature of the
research on the telephone were visited at home for their first QOL
assessment. During the first QOL assessment, the nurse obtained
informed consent. Patients were then asked to complete ques-
tionnaires themselves. Patients who asked for help at this point
either were encouraged to continue with questionnaire self-
completion or questionnaires were interview administered. Time
taken to complete questionnaires and the degree of help required
was recorded. The degree of help was categorised into no help, a
little help (brief explanation of a few items), quite a bit (help with
almost all items) or a lot of help (the questionnaire was read to the
patient).
Follow-up assessments
Patients who had required a lot of help at the baseline assessment
to complete the questionnaires continued to receive this degree of
support during follow-up. Other follow-up assessments were
arranged by telephone and performed by post. Patients with
declining health, not due to attending the hospital or those with a
poor prognosis, were offered a home visit. Patients failing to return
postal questionnaires received one telephone call reminder.
Reasons for withdrawing from QOL follow-up were recorded.
Follow-up QOL assessments continued to be offered even after
diagnosis of recurrent or progressive disease unless the nurses felt
that it was inappropriate because of the patient’s deterioration.
Timing of QOL assessment
Baseline data were collected within 3 weeks before treatment and
follow-up data were collected within 2 weeks either side of
scheduled assessments. The schedule for follow-up QOL assess-
ments varied according to treatment protocol. These are shown in
Figure 1.
Quality of life questionnaires
Quality of life was assessed with the European Organisation for
Research and Treatment of Cancer (EORTC) core QOL ques-
tionnaire, the EORTC QLQ-C30 and a site-specific module for
oesophageal or gastric cancer (Aaronson et al, 1993). The QLQ-
C30 has been reported in detail elsewhere and has been validated
in patients with many diagnoses including cancer of the upper
gastrointestinal tract. The oesophageal (QLQ-OES18) and gastric
(QLQ-STO22) modules have undergone strict questionnaire
development and are widely used (Blazeby et al, 1996; Vickery
et al, 2001). The QLQ-OES18 has recently completed international
validation testing (Blazeby et al, 2003) and the QLQ-STO22 is
currently being validated in EORTC protocol 15012.
Data analyses
Patients were followed until death or the end of the study period
(September 2002) when all surviving patients were censored. The
actual and expected numbers of QOL assessments obtained were
calculated for all patients according to the data collection schedule
(Figure 1) and survival time. Follow-up assessments declined by
patients within 6 weeks of death were not included as an expected
assessment. The impact of clinical and sociodemographic factors
on the need for help to complete questionnaires was explored
using logistic regression. Marital status was not included because
it closely linked to living situation. Gender, living situation
and treatment group were dichotomised (male, yes/no; living
alone, yes/no, curative treatment, yes/no). Education was collapsed
to three variables and age was included as a continuous
measure. Data were analysed in STATA version 7.0 and SPSS
version 10.00.
RESULTS
In total, 141 patients were eligible to take part in the QOL study. A
total of 12 (9%) did not participate for the following reasons: four
patients’ relatives felt that it was inappropriate, two patients were
too upset, three said that they were too ill to complete
questionnaires and two refused without explanation. The nurse
did not approach one patient because his wife died the preceding
week. Three patients not participating in the study were embarking
on neoadjuvant chemotherapy prior to surgery, eight were receiving
treatment aimed at palliation (endoscopic stent or chemotherapy)
and one was receiving best supportive care. Complete baseline QOL
assessments were therefore obtained from 128 patients (91%), 90
and 38 with oesophageal and gastric cancer, respectively.
Baseline QOL assessment
At the baseline assessment, 77 (60%) patients were able to
complete the questionnaires without any help from the research
nurse. A total of 10 patients required minor explanation of one or
two items. These 87 patients were grouped together as not
requiring help (Group 1). The remaining 41 patients formed Group
2. This included patients needing a lot of help from the nurse to
complete it themselves (n¼ 7) and patients who required the
questionnaire read aloud (n¼ 34). The time taken to complete the
questionnaires was similar in both groups of patients, and
sociodemographic and clinical details were similar except for
treatment group (Tables 1 and 2).
**Follow up assessments performed within 2 weeks before or after the expected date.
*Baseline assessments performed within 3 weeks before the start of treatment.
6 week assessment, then 3 monthly in 1st year**
SurgeryNeoadjuvant therapy
Monthly assessments until death or withdrawal from the study**
3 weeks* 3 weeks6 weeks
3 weeks*
Start of treatment (endoscopic palliation, chemotherapy)
Treatment with curative intent
Treatment with palliative intent
Figure 1 Timing of QOL assessment per treatment protocol. *Baseline
assessments performed within 3 weeks before the start of treatment.
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Multivariable logistic regression adjusting for age and gender
demonstrated that there was moderate evidence that the lower the
performance score the more likely that help would be required (for
a drop in performance score of 1 point, odds ratio¼ 1.03; for a
drop of 10 points, odds ratio¼ 1.34, that is a 34% increase in
odds for needing help). Moreover, patients undergoing treatment
with palliative intent were nearly three and a half times more
likely to need help than those undergoing potentially curative
treatment (odds ratio¼ 3.48, 95% confidence intervals 1.41–8.55)
(Table 2).
Follow-up
In all, 80 died during follow-up. The median survival for whole
group was 45 weeks (range, 1 day to 97 weeks). During follow-up,
810 QOL assessments were performed from an expected total of
834 (97%). Only 14 (11%) patients had one or more missing QOL
assessment. These were mostly because of progressive disease
(n¼ 11). One patient with a large alcohol intake refused follow-up,
one patients’ wife requested to drop out of the study and one
patient refused follow-up without explanation. Compliance with
follow-up was better in patients receiving help from the nurses to
complete questionnaires (Table 1).
Notably of 62 patients who were phoned for a follow-up QOL
assessment within 6 weeks of subsequent death, 48 (77%) agreed to
return a questionnaire or be visited at home.
Questionnaires in the curative treatment group were initially
administered by post in all except two patients (one was blind).
Patients who developed recurrence during the study were offered
home visits for QOL assessments. Of patients whose treatment was
Table 1 Clinical and sociodemographic details of patients needing help to complete baseline questionnaires
No help (Group 1) n¼ 87 Help (Group 2) n¼ 41
Mean age (standard deviation) 67 (10.5) 71 (11.6)
Gender
Men (%) 66 (76) 29 (71)
Women 21 (24) 12 (29)
Karnofsky performance status
Mean (standard deviation) 81 (12) 73 (13)
Living situation
Living with others (%) 18 (21) 12 (29)
Living alone 69 (79) 29 (71)
Highest level of education (%)
Less than school 8 (9) 9 (22)
Compulsory school 58 (67) 24 (59)
Post compulsory school 21 (24) 8 (19)
Diagnosis
Oesophageal cancer 59 (68) 31 (76)
Gastric cancer 28 (32) 10 (24)
Time taken to complete questionnaires (%)
o15 min 68 (78) 31 (76)
16–30 min 15 (17) 9 (22)
430 min 4 (5) 1 (2)
Undergoing radical treatment (total) (58) (67%) (13) (32%)
Oesophagectomy or radical gastrectomy 24 4
Neoadjuvant treatment and surgery 30 9
Primary chemoradiotherapy 4 —
Undergoing palliative treatment (total) (29) (33%) (28) (68%)
Palliative chemotherapy 12 7
Endoscopic palliation 8 12
Palliative bypass surgery 5 2
Best supportive care 4 6
Compliance with follow-up (%)
0 missing assessments 77 (89) 37 (90)
X1 missing assessments 10 (11) 4 (10)
Table 2 Logistic regression model examining factors relating to needing help to complete QOL
questionnaires
Variables Odds ratio Confidence intervals P-value
Age (per year increase) 1.01 0.97–1.05 0.72
Gender (women vs men) 1.42 0.57–3.55 0.46
Treatment intent (palliative vs curative) 3.48 1.41–8.55 o0.007
Performance status (per unit increase) 0.97 0.94–1.00 0.088
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palliative in intent (who mostly needed a lot of help at baseline) all
had nurse-led follow-up assessments except three patients who
completed postal assessments.
DISCUSSION
This study demonstrates that a nurse-led service to collect
longitudinal QOL data may achieve high baseline QOL compliance
and good follow-up in patients with upper gastrointestinal tract
cancer. Patients undergoing potentially curative treatment may
have QOL questionnaires administered by post with additional
telephone reminders. Patients with advanced disease, however, or
those not fit for radical treatment are more likely to need help to
complete QOL questionnaires and require an interview adminis-
tered assessment, either in the hospital or at the patients’ home.
Patients with poor performance scores may need help to complete
questionnaires, although in this study sample this did not reach
statistical significance.
The EORTC QLQ-C30 and a site-specific module assessed QOL
in this study. These instruments provide multidimensional QOL
data, but patients are required to complete more than 50 items.
Others advocate using global single-item QOL indicators to
implement QOL end points in cancer clinical trials (Sloan, 2002).
This approach has clear cut advantages, but may yield less reliable
data and reduce discriminant validity (Bernhard et al, 2001). Other
disadvantages of single-item QOL indicators are that they are less
precise for specific treatment effects than multiitem scales.
Detailed information about patients undergoing treatment with
curative intent is useful to monitor symptoms and aid patient care.
Detailed information about specific problems during palliative
treatment is also important to ensure that care is targeted
appropriately. Other QOL questionnaires designed specifically
for palliative care may include existential well being and spiritual
domains, but there are no single measures that cover physical,
psychological and spiritual domains in a format that will provide
sufficient and reliable information (Hearn and Higginson, 1997).
In addition, few measures include an assessment of dysphagia,
which is an important symptom to assess in patients with cancer of
the upper gastrointestinal tract. The EORTC oesophageal and
gastric modules include this and other relevant symptoms that
most clinicians consider important in evaluation of treatment
(Blazeby et al, 1996; Vickery et al, 2001; Blazeby et al, 2003).
In this single-centre study, repeated QOL assessments were
performed successfully in nearly 90% of patients. This is unusual,
but because of the design of the study it is not possible to know
how a nurse-led QOL service compares with other methods of QOL
data collection. A few authors have reported high accrual with
longitudinal QOL assessment in upper gastrointestinal cancer.
Buhl et al reported good compliance by using a semistructured
interview in all assessments. A more recent small study comparing
laser augmented by brachy therapy vs laser alone in palliation of
adenocarcinoma of the oesophagus also had good QOL accrual
(Spencer et al, 2002). The authors attributed this to the brevity of
the QOL questionnaire. There are no details available, however,
about how questionnaires were administered and who collected the
data. Such information is required when reporting QOL data
particularly from a population with a poor prognosis as well as
other important methodological criteria for assessing QOL (Lee
and Chi, 2000). In this current study, patients’ willingness to
continue with questionnaire completion may be attributed to the
expertise of the research nurses who were able to provide both
specialist advice (often nutritional) and psychological support for
the patient and family during the course of the illness.
In addition to achieving a high level of follow-up, QOL
assessments were performed in 77% of patients within 6 weeks
of their subsequent death. This testifies to the good relationships
that the research nurses had developed with the patients who were
happy to complete questionnaires despite being frail and unwell.
There is also some evidence to suggest that completion of QOL
questionnaires is beneficial to the patients per se because it
empowers patients to talk about aspects of their general health that
are not usually discussed during follow-up (Velikova et al, 2002).
This study achieved good follow-up questionnaire compliance, but
because of the design of the study, it is not possible to conclude
that nurses are essential to ensure high compliance with QOL data.
The standard of reporting clinical trials is fundamental to the
interpretation of individual studies and the conduct of systematic
reviews. Guidelines have been published for assessing QOL in
clinical trials from several organisations (De Haes et al, 2000;
Kiebert et al, 2001). This provides investigators with practical
information. Despite these guidelines, improvements are still
needed in QOL data collection and reporting (Sanders et al, 1998;
Lee and Chi, 2000). This study provides evidence to support the
need for dedicated research staff to obtain QOL data in clinical
trials in upper gastrointestinal tract cancer. If assessment of QOL is
the primary end point in a clinical trial such investment is
essential, and for trials where QOL is a secondary end point careful
consideration as to how QOL should be incorporated into the trial
is necessary.
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